

ONLINE SUPPLEMENTARY MATERIAL

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254

Christoph D. Spinner,¹ Franco Felizarta,² Giuliano Rizzardini,^{3,4} Patrick Philibert,⁵ Essack Mitha,⁶ Pere Domingo,⁷ Christoph J. Stephan,⁸ Michelle DeGrosky,⁹ Veronica Bainbridge,¹⁰ Joyce Zhan,¹¹ Teodora Pene Dumitrescu,¹¹ Jerry L. Jeffrey,¹² Jianfeng Xu,¹³ Fiona Halliday,¹⁰ Jianjun Gan,¹¹ Mark Johnson,¹² Martin Gartland,¹² Samit R. Joshi,⁹ Max Lataillade⁹;
208132 Study Team

¹Technical University of Munich, School of Medicine, University hospital rechts der Isar, Department of Internal Medicine II, Munich, Germany; ²Office of Franco Felizarta, MD, Bakersfield, CA, USA; ³Infectious Diseases, ASST Fatebenefratelli Ospedale Sacco, Milan, Italy; ⁴School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa; ⁵Infectious Disease, Hôpital Européen de Marseille, Marseille, France; ⁶Newtown Clinical Research, Johannesburg, South Africa; ⁷Infectious Diseases Unit, Hospital Santa Creu i Sant Pau, Barcelona, Spain; ⁸Infectious Diseases Unit, Universitätsklinikum Frankfurt, Frankfurt, Germany; ⁹ViiV Healthcare, Branford, CT, USA; ¹⁰GlaxoSmithKline, Stockley Park, UK; ¹¹GlaxoSmithKline, Collegeville, PA, USA; ¹²ViiV Healthcare, Research Triangle Park, NC, USA; ¹³GlaxoSmithKline, Upper Providence, PA, USA

Table of Contents

Supplementary Methods	3
-----------------------------	---

Supplementary Methods

Exclusion Criteria

Relevant exclusion criteria included positive test results for active hepatitis B, hepatitis C, alanine aminotransferase levels $>2\times$ the upper limit of normal, and bilirubin levels $>1.5\times$ the upper limit of normal. Individuals were excluded if they had a history of psychiatric disorders; received an immunomodulatory or anti-HIV agent within 30 days; or had primary HIV infection, ongoing nonlocalized malignancy, or any active Centers for Disease Control and Prevention category C disease.

Sample Collection Times

Plasma HIV-1 RNA was assessed predose at each visit in parts 1 and 2 and quantified using polymerase chain reaction assay. Blood samples collected predose on Days 1 and 11 in part 1 and Days 1 and 8 in part 2 were analyzed for HIV-1 genotypic and phenotypic testing conducted by Monogram Biosciences (South San Francisco, CA). Genotype was assessed using next-generation sequencing. Blood samples were collected predose for a single PK assessment on Days 3 or 4 in parts 1 and 2; Days 5, 6, or 7 in part 1; and Days 5 or 6 in part 2. Blood samples for intensive PK sampling were collected predose and 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Days 1 and 8, 9, or 10 in part 1 and Days 1 and 7 in part 2.